unities for increased sales. Technological innovations, including R&D biotechnology products and the Internet as a locus for supply chain integration also affect the firm. Environmental concerns related to scarcity of resources, competition, and industry mergers and acquisitions also affect the firm. Politically, governmental regulatory shifts (specifically increased funding for prescription drugs for older Americans and FDA activities) shape the firm's potential profitability while simultaneously constraining efforts to move new drugs rapidly through the approval pipeline (Hamer, 2003).
2.6 Mullin (2002) asserted that though this sector is continuing to grow, it is beset by a number of variables that are directly reshaping its fundamental structure as well as its profitability. Wing and Perry (2001) contend that leading life sciences enterprises try to bring the same degree of rigor to their business processes as they do to drug discovery or consumer products testing. Although some pharmaceutical companies produce breakthrough drugs and deliver outs
...